KEAP1 and Cognitive impairment: Taken together, these findings suggest that the Keap1—Nrf2 system may play a role in the cognitive impairment that is observed in schizophrenia, and that SFN, an activator of Nrf2, may have preventive or therapeutic effects on cognitive impairment in patients with psychiatric diseases such as schizophrenia.